Tayyebeh Tavakoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tayyebeh Tavakoli has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Pedram Basirjafar
Department of Immunology, School of Medicine Rafsanjan University of Medical Sciences Rafsanjan Iran
3 shared publicationsRaziyeh Zandvakili
Department of Immunology, School of Medicine Rafsanjan University of Medical Sciences Rafsanjan Iran
3 shared publications- Abdollah Jafarzadeh
Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
2 shared publications Javad Masoumi
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
2 shared publicationsZahra Taghipour
Department of Anatomy, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
2 shared publicationsAbdollah Jafarzadeh
Department of Immunology, School of Medicine Kerman University of Medical Sciences Kerman Iran
1 shared publication
Latest Publications
- 23 February 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (2) , e70185
Inhibition of the Apelin/APJ Axis Modulates Type 1 Cytotoxic T Cell and Type 2 Cytotoxic T‐Related Immune Responses in an Animal Model of Metastatic Breast Cancer
Apelin, an adipose‐derived peptide, is overexpressed in the microenvironment of various tumors, modulating anti‐tumor immune responses. In the immune system, cytotoxic T cells perform a fundamental role in cancerous cell elimination. Therefore, inhibiting apelin/APJ can prevent apelin‐induced immunosuppression. In this study, we investigated the impact of an apelin receptor antagonist, ML221, on modulating type 1 cytotoxic T (TC1) and TC2 lymphocyte‐associated parameters in mice with breast cancer (BC). BC was generated in BALB/c mice by subcutaneous inoculation of 4T1 malignant cells. Phosphate‐buffered saline (PBS) or ML221 was administered to the BC‐bearing animals for 21 days, starting at 15 days following tumor cell injection. After animal euthanasia on day 37, serum IL‐12/IL‐4 concentrations and the frequency of splenic TC1/TC2 cells were measured by ELISA and flow cytometry techniques, respectively. BC metastasis to the liver was examined by hematoxylin and eosin staining. Treatment of BC animals with ML221 was more efficient in decreasing tumor growth ( p < 0.002), avoiding liver metastases ( p < 0.0001), and enhancing the rate of survival ( p = 0.001) in comparison to the non‐treated group. When compared to the non‐treated group, treatment with ML221 substantially raised the frequency of TC1 cells and the TC1/TC2 ratio in the spleen ( p < 0.01). Serum IL‐12 concentrations and the IL‐12/IL‐4 ratio were likewise higher in BC mice treated with ML221 ( p < 0.05). TC1‐associated anti‐tumor responses can be improved by apelin/APJ axis suppression, which can contribute to decreasing tumor growth and progression.
- 23 February 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (2) , e70185
Inhibition of the Apelin/APJ Axis Modulates Type 1 Cytotoxic T Cell and Type 2 Cytotoxic T‐Related Immune Responses in an Animal Model of Metastatic Breast Cancer
Apelin, an adipose‐derived peptide, is overexpressed in the microenvironment of various tumors, modulating anti‐tumor immune responses. In the immune system, cytotoxic T cells perform a fundamental role in cancerous cell elimination. Therefore, inhibiting apelin/APJ can prevent apelin‐induced immunosuppression. In this study, we investigated the impact of an apelin receptor antagonist, ML221, on modulating type 1 cytotoxic T (TC1) and TC2 lymphocyte‐associated parameters in mice with breast cancer (BC). BC was generated in BALB/c mice by subcutaneous inoculation of 4T1 malignant cells. Phosphate‐buffered saline (PBS) or ML221 was administered to the BC‐bearing animals for 21 days, starting at 15 days following tumor cell injection. After animal euthanasia on day 37, serum IL‐12/IL‐4 concentrations and the frequency of splenic TC1/TC2 cells were measured by ELISA and flow cytometry techniques, respectively. BC metastasis to the liver was examined by hematoxylin and eosin staining. Treatment of BC animals with ML221 was more efficient in decreasing tumor growth ( p < 0.002), avoiding liver metastases ( p < 0.0001), and enhancing the rate of survival ( p = 0.001) in comparison to the non‐treated group. When compared to the non‐treated group, treatment with ML221 substantially raised the frequency of TC1 cells and the TC1/TC2 ratio in the spleen ( p < 0.01). Serum IL‐12 concentrations and the IL‐12/IL‐4 ratio were likewise higher in BC mice treated with ML221 ( p < 0.05). TC1‐associated anti‐tumor responses can be improved by apelin/APJ axis suppression, which can contribute to decreasing tumor growth and progression.
- 6 July 2024
- Published by Springer Nature in Advances in Traditional Medicine
- Vol. 24 (4) , 1215-1227
Effect of a traditional herbal formulation (Azaraghi Majoon) on opium use disorder in male rats
- 6 July 2024
- Published by Springer Nature in Advances in Traditional Medicine
- Vol. 24 (4) , 1215-1227
Effect of a traditional herbal formulation (Azaraghi Majoon) on opium use disorder in male rats
- 30 March 2023
- Published by Elsevier in Advances in Medical Sciences
- Vol. 68 (1) , 157-168
Vaccination with celecoxib-treated dendritic cells improved cellular immune responses in an animal breast cancer model
- 30 March 2023
- Published by Elsevier in Advances in Medical Sciences
- Vol. 68 (1) , 157-168
Vaccination with celecoxib-treated dendritic cells improved cellular immune responses in an animal breast cancer model